News

Press Release: FDA grants orphan drug designation for PNH to Amyndas Pharmaceuticals’ novel complement inhibitor

October 12, 2014

“Amyndas Pharmaceuticals SA, the complement therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has granted AMY-101, a potent complement C3 inhibitor, an Orphan Drug Designation for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The U.S. FDA orphan designation comes after the European Medicines Agency (EMA) orphan status approval of AMY-101 for the same indication, less than two months ago.”

To read entire press release: www.fiercepharma.com

 

Comments are closed.